A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain
- 5 February 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 20 (3) , 500-510
Abstract
Chemotherapeutic treatment of neoplastic diseases is often restricted by adverse systemic toxicity, which limits the dose of drug that can be administered, or by the appearance of drug resistance. Therefore, novel targeted therapeutic approaches are being developed to improve current conventional therapy in order to increase specificity and biocompatibility, and decrease toxicity. Legumain represents a recently identified lysosomal protease that has been reported to be overexpressed in the majority of human solid tumors, to promote cell migration and is associated with enhanced tissue invasion and metastases. Therefore, it serves as a promising candidate for prodrug therapy. We synthesized a novel legumain-cleavable prodrug, carbobenzyloxy-alanine-alanine-asparagine-ethylenediamine-etoposide, which releases the chemotherapeutic agent, etoposide, as the active drug. The prodrug was characterized and analyzed by 1H NMR and HPLC. 293 Human embryonic kidney (293 HEK) cells were stably transfected with human legumain, to achieve overexpression in vitro (293 HEK-Leg). 293 HEK-Leg cells expressed both active and inactive legumain and secreted it to the medium. Legumain expression was found to be elevated because of serum starvation in both 293 HEK cells and PC3 human prostate carcinoma cells. The commercial substrate of legumain, carbobenzyloxy-alanine-alanine-asparagine-amino-4-methyl coumarin (CBZ-Ala-Ala-Asn-AMC) and the synthesized prodrug were both cleaved by recombinant human legumain (rhlegumain) and legumain expressed in the 293 HEK-Leg cell lysate. Upon cleavage by rhlegumain, the prodrug showed an inhibitory effect on the proliferation of 293 HEK and 293 HEK-Leg cells. This study suggests a novel platform for prodrug therapy activated by legumain as a promising approach for cancer therapy.Keywords
This publication has 28 references indexed in Scilit:
- Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cellsFEBS Letters, 2007
- Targeting tumor-associated macrophages as a novel strategy against breast cancerJournal of Clinical Investigation, 2006
- Polymer Therapeutics: Concepts and ApplicationsAngewandte Chemie International Edition, 2006
- Targeting Cell-Impermeable Prodrug Activation to Tumor Microenvironment Eradicates Multiple Drug-Resistant NeoplasmsCancer Research, 2006
- Legumain Expression in Relation to Clinicopathologic and Biological Variables in Colorectal CancerClinical Cancer Research, 2005
- Biosynthetic Processing of Cathepsins and Lysosomal Degradation Are Abolished in Asparaginyl Endopeptidase-deficient MiceJournal of Biological Chemistry, 2003
- Diagnostic significance of Schistosoma mansoni proteins Sm31 and Sm32 in human schistosomiasis in an endemic area in EgyptTropical Medicine & International Health, 1998
- Cloning, Isolation, and Characterization of Mammalian Legumain, an Asparaginyl EndopeptidaseJournal of Biological Chemistry, 1997
- A unique vacuolar processing enzyme responsible for conversion of several proprotein precursors into the mature formsFEBS Letters, 1991
- The Clinical Pharmacology of Etoposide and TeniposideClinical Pharmacokinetics, 1987